February 10, 2023Open Access

Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors

Key Points

Key points are not available for this paper at this time.

Abstract

TP53 mutations represent a clinically relevant mechanism of resistance to EGFR-TKIs, regardless of their generation. A personalized therapeutical approach should be explored in dedicated clinical trials.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Ferrara et al. (Fri,) studied this question.

synapsesocial.com/papers/69d861d38cb8f39931ae31d6 https://doi.org/https://doi.org/10.1016/j.critrevonc.2023.103929

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement2009 · 83,350 citations
2Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study2013 · 127 citations
3Meta-analysis in clinical trials revisited2015 · 2,656 citations
4Epithelial–mesenchymal transition: a new target in anticancer drug discovery2016 · 353 citations
5High-Throughput Tissue Microarray Analysis Used to Evaluate Biology and Prognostic Significance of the E-Cadherin Pathway in Non–Small-Cell Lung Cancer2002 · 283 citations

KI fragen

Bookmark

View Full Paper